Insilico Medicine is a globally leading biotechnology company that utilizes artificial intelligence (AI) for every step of pharmaceutical research and development. They combines genomics, big data analysis, and deep learning for in silico drug discovery.
They have a mission to extend healthy productive longevity by transforming drug discovery and development with generative artificial intelligence. This significantly reduces the time and cost to bring life-saving medications to patients. As of 2023, Insilico Medicine has 32 investors and is preparing for Phase 2 of AI-accelerated drug discovery. They also have a pulmonary fibrosis drug in Phase 2 clinical trials.